Inhibition of an initiating oncogene often leads to extensive tumour cell death, a phenomenon known as oncogene addiction 1 . This has led to the search for compounds that specifically target and inhibit oncogenes as anticancer agents. However, there has been no systematic exploration of whether chromosomal instability generated as a result of deregulation of the mitotic checkpoint pathway 2,3 , a frequent characteristic of solid tumours, has any effect on oncogene addiction. Here we show that induction of chromosome instability by overexpression of the mitotic checkpoint gene Mad2 in mice does not affect the regression of Kras-driven lung tumours when Kras is inhibited. However, tumours that experience transient Mad2 overexpression and consequent chromosome instability recur at markedly elevated rates. The recurrent tumours are highly aneuploid and have varied activation of pro-proliferative pathways. Thus, early chromosomal instability may be responsible for tumour relapse after seemingly effective anticancer treatments.
Chromosomal instability (CIN) is commonly found in human solid tumours, and extensive studies with mouse models suggest that it is sufficient to initiate tumorigenesis in a variety of cellular contexts [4] [5] [6] .
We have previously reported that ubiquitous overexpression of Mad2, which induces whole-chromosome instability and rearrangements 3 , is sufficient for tumour initiation in multiple tissues including lung 3 .
To determine whether CIN imparted by Mad2 overexpression could accelerate tumour formation driven by a classical oncogene, we generated cohorts of mice carrying a type II alveolar epithelial cellspecific doxycycline-inducible (CCSP-rtTA) transactivator transgene 7 in addition to rtTA-responsive Mad2 and/or murine oncogenic K-Ras4b G12D transgenes 8 . Resulting progeny were divided into groups maintained on normal or doxycycline diets at weaning. We refer to these mice as TI-K, TI-M and TI-KM for 'tetracycline inducible' Kras, Mad2 and Kras 1 Mad2, respectively. Eight weeks after induction, western blot analysis of lungs confirmed that only those mice exposed to doxycycline expressed exogenous Mad2 protein, resulting in levels that were double those in control animals ( Fig. 1a ). Endogenous levels of Mad2 were not upregulated on Kras G12D activation ( Fig. 1a and Supplementary Fig. 1a ).
Eight weeks after transgene induction, the lungs of TI-KM mice were nearly twice as large as those of TI-K mice ( Fig. 1b ) and total tumour area was significantly increased (Fig. 1c ). However, tumour nodule number was not increased (Fig. 1e ), indicating that tumour initiation is not affected by Mad2 overexpression. Adenocarcinomas in TI-KM mice showed a more aggressive morphology, with invasion into the pleura and higher proliferation rates ( Fig. 1d-f ) but no significant differences in apoptosis ( Fig. 1d ). Moreover, a statistically significant decrease in survival was seen in TI-KM versus TI-K mice. Whereas TI-K mice survived for 543 6 32 days (mean 6 s.e.m.), TI-KM mice survived for 258 6 11 days (mean 6 s.e.m.) (P , 0.0001) ( Fig. 1g ). All mice died of lung tumours, as determined by postmortem examination. Although overexpression of Mad2 by itself under the cytomegalovirus (CMV) promoter induces lung tumours in 35% of animals 3 , only 1 in 40 Mad2-overexpressing mice (TI-M) in a Kras wild-type background harboured a lung adenoma after 15 months on doxycycline (data not shown). This may be the result of Mad2 transgene expression being restricted to type II pneumocytes in the CCSP-rtTA model compared with ubiquitous overexpression in CMV-rtTA mice. Neither total nor exogenous levels of Mad2 in TI-KM animals were higher than in TI-M mice, making it likely that the increase in tumour burden is dependent on combined Kras and Mad2 overexpression ( Supplementary Fig. 1a In both TI-K and TI-KM mice, lung adenocarcinomas were SP-C positive, which is consistent with a type-II-like classification (Supplementary Fig. 2a, b ), and negative for Clara cell secretory protein (CCSP) 8 ( Supplementary Fig. 2c, d ), which was seen in normal cells lining the airways ( Supplementary Fig. 2e , f). Hence, combined lungspecific Mad2 and Kras overexpression leads to the formation of lung adenocarcinomas that are more aggressive than, although histologically similar to, those seen with Kras alone.
We have previously reported that ubiquitous overexpression of Mad2 leads to tumour initiation through the acquisition of a CIN phenotype 3 . To determine whether the CIN generated by high levels of Mad2 could be contributing to the more severe phenotype in TI-KM mice, fluorescence in situ hybridization (FISH) analysis was performed on lung tissue, with chromosomes 12, 16 and 17 specific probes. TI-K lung tumours showed higher levels of aneuploidy (13%) than normal lung (2%, not shown). However, TI-KM tumours showed a threefold increase in aneuploid cells over TI-K (38% versus 13%, P , 0.0001) ( Fig. 2a, b ). TI-M animals developed very low levels of aneuploidy (5.7%), which is consistent with the observed lack of tumour formation. Despite high rates of aneuploidy seen in TI-KM primary tumours, array comparative genomic hybridization (CGH) analysis failed to detect any gross abnormalities (data not shown). This most probably reflects the absence of stable, clonally propagated events that contribute significantly to the CGH profile.
RNA microarray analysis confirmed the diversity of tumour subtypes in the Kras and Mad2 tumours. Whereas the majority of Kras tumours clustered together, the TI-KM primary tumours were markedly different from each other and from the cluster of mutant Kras overexpressors. These results suggest that Mad2 overexpression induces a wide spectrum of chromosomal aberrations and expression changes that are probably contributing to enhanced tumorigenesis. The precise causative events have not been identified ( Supplementary  Fig. 3 ).
Continued expression of mutant Kras is required for tumour maintenance 8 . In contrast to what is observed with classical oncogene overexpression, continuous Mad2 overexpression is not required for tumour maintenance, because primary tumours induced after Mad2 overexpression in two different ubiquitous inducible model systems do not regress on transgene de-induction 3 . To determine whether the CIN imparted by Mad2 overexpression affected Kras oncogene addiction, TI-K or TI-KM mice with lesions evident by magnetic resonance imaging (MRI) were identified (Supplementary Table 1 ) and then switched to a regular diet. MRI performed two weeks after de-induction revealed a striking decrease in tumour volume in both TI-K and TI-KM mice ( Fig. 2c and Supplementary Fig. 4 ). Examination of lungs from all mice confirmed normal histology with areas of pleural and parenchymal fibrosis. Thus, CIN associated with Mad2 overexpression is not sufficient to prevent tumour regression after abrogation of Kras and Mad2 expression. It is likely that these tumours regress in response to mutant Kras withdrawal and not Mad2, because, as stated above, de-induction of Mad2 in the CMV-rtTA and tTA systems never leads to tumour regression by itself 3 .
Next, we sought to determine whether CIN would affect the rate of tumour recurrence. A total of 25 TI-K and 24 TI-KM mice maintained on doxycycline were monitored for tumour appearance by MRI (Supplementary Table 2 ). When solid tumours were identified (between 12 and 28 weeks), doxycycline was removed from the diet and the mice were periodically screened for tumour regrowth. Whereas TI-K tumours never relapsed after de-induction of the oncogene (even up to one year after withdrawal of doxycycline), tumours recurred in 11 out of 24 TI-KM mice killed 4-11 months after doxycycline withdrawal ( Fig. 3a, b ). These nodules were solid or well-defined proliferating papillary adenocarcinomas that were morphologically indistinguishable from the primary tumours (Fig. 3e) . The presence of recurrences in TI-KM animals was not a result of the larger primary tumour size, because even in TI-KM animals selected for a small tumour volume a 50% recurrence was observed ( Fig. 3c and Supplementary Table 3 ). In fact, the average volume of primary KM tumours that went on to recur in this selected population was significantly smaller than that of K and of KM primaries that never recurred (Fig. 3c ). The overexpression of Mad2 alone led only to a single tumour in 1 out of 40 animals after 15 months of induction, making it likely that the KM relapses were dependent on having expressed both transgenes.
It is, however, formally possible that these recurrences are de novo tumours derived from cells that had expressed Kras and Mad2 but were not part of the initial tumour mass, a possibility that we consider unlikely for the following reasons: first, no such events have been reported in other inducible mouse models of oncogene addiction 9,10 ; second, TI-KM animals maintained off doxycycline never develop lung tumours in this model system; third, TI-KM mice that were on doxycycline for 5 weeks, during which time no tumours developed, and switched to a regular diet for 35 additional weeks did not develop tumours ( Supplementary Fig. 5 ); and fourth, in 3 out of 3 informative cases in which primary tumours were small enough to localize by MRI, recurrences appeared at the same anatomical site as the primary tumour (Fig. 3a) .
Tumour relapse has been observed in several tetracycline-inducible mouse models of oncogene addiction 11 . Although many of these recurring tumours show doxycycline-independent re-expression of the transgene, additional mechanisms responsible for tumour recurrence have also been identified. We performed haemagglutinin (HA)specific immunohistochemistry and/or RT-PCR analysis to detect the Mad2 and Kras transgenes in the primary tumours, recurrent lesions and tumour-free lung samples from TI-K and TI-KM mice (Fig. 3d, e, and Supplementary Fig. 6b ). None of the non-tumourbearing lungs after doxycycline withdrawal re-expressed the inducible transgenes. Only one of the recurrences re-expressed the Kras transgene and 2 out of 11 re-expressed the Mad2 transgene (which by itself is insufficient to induce tumour formation), suggesting modes of escape that are independent of the initiating oncogene. RT-PCR and sequencing of commonly mutated exons revealed that the recurrences were not a result of secondary point mutations in the endogenous Hras, Kras or Nras loci (data not shown), a common mechanism of acquired resistance to targeted therapies in other inducible mouse models 12 and in human cancer [13] [14] [15] .
In parallel to what was seen with the primary tumours, recurrent tumours in TI-KM mice were highly aneuploid (39.4%). Lung tissue from TI-K animals after tumour regression showed very low levels of aneuploidy (2.7%), similar to that in wild-type lung, suggesting that this baseline aneuploid level is insufficient to drive tumour recurrence. In contrast, elevated rates of aneuploidy were observed both in the TI-KM primary tumours (38%) and TI-KM lungs after regression (12.9%) before tumour relapse. This suggests that high levels of aneuploidy in the primary tumour and in cells remaining after deinduction of Kras and Mad2 enable survival after oncogene withdrawal, thereby facilitating relapse (Fig. 4a, b) .
Kras G12D lung tumours show positive staining for pErk, pStat3, pAkt and pS6, indicating that the mitogen-activated protein kinase (MAPK), STAT3 and phosphoinositide 3-kinase pathways are all stimulated by oncogenic Kras 16 (Supplementary Fig. 7 ). Only five out of ten KM recurrences retained MAPK pathway activation, and four out of ten showed low-level pStat3 activity ( Fig. 4c and Supplementary Fig. 8 ). Ten out of ten recurrences scored positive for AKT, though the different levels and patterns seen by immunohistochemistry make this unlikely to be the sole determinant of recurrence. For further characterization of the signalling pathways implicated in tumour relapse, RNA microarray analysis was performed in six TI-KM recurrent tumours. Consistent ( Supplementary Fig. 9 ) with the immunohistochemistry analysis, recurrent tumours were very heterogeneous, different from each other and from the K or KM primary tumours. Thus, recurrent tumours use alternative signalling pathways to escape oncogene addiction, a result consistent with the notion that Mad2-mediated CIN in the primary tumour provides extensive diversity and therefore an evolutionary advantage to oncogene-driven solid tumours.
The role of aneuploidy in the initiation of human tumours has been modelled extensively in mice 5, 17, 18 . Overexpression of the mitotic checkpoint gene Mad2 is a very common occurrence in human tumours, probably due to its direct activation by E2F when the retinoblastoma tumour suppressor pathway is inhibited 2 . Indeed, inducible overexpression of Mad2 in mice leads to modest levels of aneuploidy and robust tumour induction in multiple tissue types 3 . Extremely high levels of aneuploidy are observed in cells with complete loss of mitotic checkpoint function [19] [20] [21] , but these cells are non-viable, a fact reflected in the observation that no mitotic checkpoint-null tumours have ever been reported, regardless of p53 status. Although loss of mitotic checkpoint function in some settings can suppress tumour formation in vivo [22] [23] [24] , whether this is due to intolerable levels of aneuploidy and subsequent cell death or perhaps even non-cell autonomous effects on the tumour microenvironment has not yet been examined.
The requirement for continued expression of an initiating oncogenic stimulus for tumour cell survival (oncogene addiction 1 ) is a puzzling phenomenon, because withdrawal of a deregulated activity might be predicted to lead to reversion of the cell to a normal state. Nonetheless, its occurrence suggests that therapeutic targeting of oncogenes might lead to profound tumour regression. Indeed, inhibition of the deregulated kinase activity of bcr-abl with the drug imatinib (Gleevec) in chronic myelogenous leukaemia is an extremely effective targeted therapy 25 . Patients in the accelerated phase of the disease, in which multiple chromosomal anomalies are observed, still show a strong clinical response, although with significantly higher relapse rates [26] [27] [28] . Here we show that a similar phenomenon might take place in solid tumours. CIN induced by overexpression of the mitotic checkpoint gene Mad2 (observed in a wide variety of human tumours) does not alleviate addiction to Kras in a lung tumour model, because profound tumour regression takes place when Kras expression is inhibited whether or not CIN is present in the primary lesion. However, a marked increase in tumour recurrence occurs in the chromosomally unstable setting with emergent independence from the original oncogenic stimulus. Although resistance to targeted therapies is often initially due to point mutations or amplifications of the intended target gene, CIN might provide an escape route even after sequential, successful inhibition of the altered target. Moreover, CIN in the primary tumour may accelerate the disruption of DNA repair pathways, thereby facilitating the generation of point mutations. Thus, early CIN in tumours, which in some cases results directly from the loss of the retinoblastoma tumour suppressor pathway and overactivation of the mitotic checkpoint, may provide the evolutionary fuel responsible for high relapse rates in human cancers that initially respond to targeted or perhaps even conventional chemotherapeutic regimens. Mouse models of cancer that often show benign levels of CIN relative to human cancers may thereby overestimate the efficacy of clinical drug candidates.
METHODS SUMMARY
All mice (TI-K, TI-KM, TI-M, CCSP-rtTA) were of mixed 129/Bl6 background. Doxycycline (625 p.p.m.) was administered in impregnated food pellets (Harlan-Teklad). For MRI analysis, mice were anaesthetized with isofluorane and images were obtained by a low-resolution axial scout followed by a high-spatial resolution T2 weighted scan. FISH analysis was performed with three pericentromeric probes from chromosomes 12, 16 and 17 amplified from corresponding bacterial artificial chromosome (BAC) clones and labelled by nick translation with SpectrumGreen, SpectrumRed and SpectrumOrange fluorophores. Quantification of aneuploidy was conducted in a minimum of 150 interphase nuclei counterstained with 4,6diamidino-2-phenylindole. Microarray expression analysis was performed on MOE430A 2.0 Affymetrix arrays with RNA extracted using the Qiagen RNeasy kit. For CGH, DNA was extracted with a Qiagen DNeasy kit, whole-genome amplified and hybridized to normal genome controls on an Agilent mouse 244K array. RT-PCR was conducted with SuperScript III (Invitrogen) in accordance with the manufacturer's instructions, and amplified with transgene-specific primers. Protein expression was assessed by western blot of 40 mg of tissue lysates incubated with antibodies against Mad2 (BD) and actin (Amersham). Histopathology and immunohistochemistry were performed on paraffin sections of formalin-fixed tissue with Ki67 (Novocastra), anti-prosurfactant protein C (Chemicon), anti-Clara cell protein (Chemicon), anti-phospho-AKT (Cell Signaling Technology), anti-phospho-Stat3 (Cell Signaling Technology), antiphospho-S6 (Cell Signaling Technology) and anti-HA (Roche). 
